This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Smith states, weve definitely come across people in the pharma industry who worry that AI means companies might steal our data or use it in harmful ways. As the industry gains more exposure to AIs real-world applications and the rigorous standards AI companies adhere to, trust will continue to grow.
DT-9046 is currently progressing through pre-IND studies, supported by a robust data package, including head-to-head benchmarks and strong patent protection.
What Pharma Sponsors Are Asking As sponsors prepare for ICH E6(R3), a few common questions have emerged: Where do we start? Many pharmacompanies are unsure how to begin aligning with the new expectations, especially around trial design and quality systems.
While Big Pharmacompanies have announced $270 billion in domestic investments, lab leasing declined significantly in Q1 2025, finds JLL’s U.S. Life Sciences Property Report.
The paper gives a useful insight into the most commonly used in vitro MetID practices across 26 pharmacompanies, and crucially reveals how effective these systems are at predicting circulating human metabolites. Hypha’s clients range from small through to large pharmacompanies.
"5 Key Considerations for Valuing PharmaCompanies As the pharmaceutical industry continues to evolve, accurately valuing pharmacompanies has become increasingly complex. Patent Portfolio Strength : A strong patent portfolio can significantly impact a company's valuation.
The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation. In 2017, small and medium-sized biotech companies accounted for 51% of FDA market approvals, while large pharmacompanies were the originators in only 28% of approvals[4].
The tariffs on pharmaceuticals would have a grace period of up to a year and a half to give drugmakers the opportunity to move their manufacturing operations to the U.S.
Even the largest of Pharmacompanies use CROs – the reason being that the in-depth scientific resources needed to support these technologies are just not cost-effective enough to have internally,” he explains. Almost without exception, CROs are involved in the development of novel therapies.
As pharmacompanies grapple with mounting pressure from regulators, payers, and evolving market dynamics, the CSO model offers a compelling alternative to traditional, fully in-house sales forces.
But what does this mean for pharmacompanies, investors, and patients? According to a recent analysis, the loss of exclusivity for top-selling medications will result in a staggering $1.4 trillion in lost revenue by 2025.
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharmacompanies' research progress. Here’s a list of conferences to watch in 2025.
tax law changes enacted six years ago slashed large pharmacompanies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.
Many pharmacompanies are now using de-identified lab data to identify potential patients and their physicians in time to impact the patient’s treatment plan. In this Q&A, learn how lab data can be used to increase patient access.
"Unlocking the Secrets to Smarter Partnerships: How One Tool is Revolutionizing the Way PharmaCompanies Approach Out-Licensing and Partnering Decisions As the pharmaceutical industry continues to evolve, companies are under increasing pressure to maximize their portfolios and minimize risk.
The Swiss pharmacompany is the latest large drugmaker to invest big in an experimental heart treatment, after years of prioritizing medicines for cancer and immune diseases.
So what does the game look like to a late-stage investor or a pharmacompany head of R&D thinking about portfolio prioritisation? By contrast, if you behave like an early-stage investor with a good quality pharmacompany pipeline, you will likely kill value by under-investing or stopping projects that have real value.
Pharmacompanies can thrive in 2024 by leveraging digital intelligence to anticipate trends, analyze sentiment, and engage audiences. Discover how data-driven insights drive success.
This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the… The post Which pharmacompanies have the most supplementary protection certificates?
Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. To learn more, check out MMIT’s Strategic Launch Report & Evaluate Forecast solution. Read on for Steve’s insights.
This chart shows the drug companies with the most supplementary protection certificates (SPCs). The post Which pharmacompanies have the most supplementary protection certificates? SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the….
This chart shows the drug companies with the most supplementary protection certificates (SPCs). The post Which pharmacompanies have the most supplementary protection certificates? SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the….
This chart shows the drug companies with the most supplementary protection certificates (SPCs). The post Which pharmacompanies have the most supplementary protection certificates? SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the….
Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1.
In their coverage of Mark Cuban’s new pharmacompany, they cited our published interview where Mark Cuban Sounds off on Drug Prices.…. DrugPatentWatch was featured in a recent article by Inc. The post DrugPatentWatch featured in Inc Magazine appeared first on DrugPatentWatch - Make Better Decisions.
In a recent article published by IAM Magazine, titled “Why PharmaCompanies Should File Patents Later In The R&D Process,” Alexander R. Trimble, PhD, a prominent patent attorney, explores the… The post Filing Strategies for Maximizing Pharma Patents appeared first on DrugPatentWatch - Make Better Decisions.
SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. .
The AI innovation race is on: Here are three strategies to ensure you’re not left behind | Biotech and pharmacompanies are using generative AI to improve business operations, marketing performance and research.
She highlights three key trends that pharmacompanies, plan sponsors, and others will consider as we head to the upcoming Asembia Specialty Pharmacy Summit (October 26 to 29 in Las Vegas). Today’s guest post comes from Jayne Hornung, Chief Clinical Officer at MMIT.
Listing Image QuartzListingLogo_250x190_norstella.png Listing Introduction Real-world data is essential to gaining insights into a patient’s diagnostic journey, but many pharmacompanies may not be using lab data, in particular, to its full potential. On Demand Start Date Tue, 10/29/2024 - 12:00
In practice, this looks much more like a traditional pharmacompany than a biotech. Global pharmacompanies, at least until recently, didn’t have “stories” linking assets but an uncorrelated pipeline of product candidates chosen for their individual value.
Discover how a top 10 pharmacompany is making strides in addressing this disparity by harnessing the power of H1's diversity insights to build an equitable clinical trial for cardiovascular disease.
They also provide a level playing field for academics, biotech companies, and pharma giants to compete on. However, Pharmacompanies do have a some advantages when it comes to the proprietary data they have on failed or patented drugs, giving them a step ahead in exploring repurposing.
Omnichannel engagement for physician marketing is a powerful tool for biotechnology and pharmacompanies looking to increase reach and drive engagement among HCPs. By taking a tailored approach, pharmacompanies can ensure they’re offering meaningful information that resonates with each individual HCP.
Fierce Biotech Week Fierce Biotech Week features insights from C-suite and executive leadership at biotech, mid-sized and large pharmacompanies on emerging trends and market dynamics that will help effectively prioritize R&D spend, optimize drug development and clinical operations, and navigate capital raising and partnering deals.
But despite the supportive landscape for rare disease therapies, pharmacompanies still struggle to launch on time, if at all. But despite the supportive landscape for rare disease therapies, pharmacompanies still struggle to launch on time, if at all.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content